-
Information on a potential supply of shares in connection with the expiration of the lock-up period for shares under the Stock Grant Program
Read More
July 8, 2022 -
Execution of an exclusive license agreement with Exelixis, Inc. to develop novel STING agonist-based targeted cancer therapies
Read More
July 7, 2022 -
Shareholders controlling at least 5% of the votes at the General Shareholders Meeting of Ryvu Therapeutics S.A. convened on June 30, 2022
Read More
July 1, 2022 -
Resolutions adopted by the General Shareholders Meeting of Ryvu Therapeutics S.A.
Read More
July 1, 2022 -
Publication of the updated phase 1b clinical and preclinical data for RVU120 and phase 1/2 SEL24 (MEN1703)
Read More
June 10, 2022 -
Convening the Ordinary General Shareholders Meeting of Ryvu Therapeutics S.A.
Read More
June 3, 2022 -
New data from RVU120 and SEL24(MEN1703) programs to be presented at the EHA Hybrid Congress 2022
Read More
May 12, 2022 -
Ryvu Therapeutics to present recent RVU120 and SEL24 (MEN1703) data at ASCO 2022 Annual Meeting
Read More
April 27, 2022 -
Notification from person discharging managerial responsibilities in the Company due to execution of the Stock Grant Program – Article 19 of MAR
Read More
April 1, 2022 -
Ryvu Therapeutics to present recent data from oncology programs at AACR 2022 Annual Meeting
Read More
March 8, 2022 -
Publication dates for periodic reports in 2022
Read More
January 19, 2022 -
Delivery of a lawsuit for payment in connection with the construction of the Research and Development Center
Read More
January 19, 2022 -
Ryvu Therapeutics to receive from Menarini Group a development milestone based on an amended global License Agreement
Read More
December 30, 2021 -
Ryvu Therapeutics receives approval to conduct Phase I/II study of RVU120 (SEL120) in patients with relapsed/refractory metastatic or advanced solid tumors in Spain
Read More
December 20, 2021 -
Change order to the statement of work
Read More
December 17, 2021 -
Galapagos NV exercises its exclusive option to license program with therapeutic potential in inflammatory diseases
Read More
December 14, 2021 -
Ryvu Therapeutics Presents Clinical and Translational Data Updates at the 63rd American Society of Hematology (ASH) Annual Meeting and the 44th San Antonio Breast Cancer Symposium
Read More
December 13, 2021 -
Notification from person discharging managerial responsibilities in the Company due to execution of the Stock Grant Program – Article 19 of MAR
Read More
November 19, 2021 -
Ryvu Therapeutics to highlight HPK1 and STING Programs at the upcoming SITC Conference
Read More
November 9, 2021 -
Ryvu’s partner Menarini Group receives FDA Orphan Drug Designation for SEL24 (MEN1703) for the Treatment of Acute Myeloid Leukemia
Read More
November 4, 2021
Report: Current Stock Reports
Title